App-Quantinova.ai

The safety profile of a selective EGFR TKI epitinib (HMPL-813) in patients with advanced solid tumors and preliminary clinical efficacy in EGFRm+ NSCLC patients with brain metastasis.

Qing Zhou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Epitinib

Effect of brain metastases on survival and systemic treatment of EGFR/ALK-driven non-small cell lung cancer (NSCLC).

Mark Doherty - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Pooled analysis of venous thromboembolism (VTE) from four trials of necitumumab and chemotherapy for stage IV non-small cell lung cancer (NSCLC).

Kelvin Young - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Carboplatin

Efficacy and safety of tamibarotene or placebo added to paclitaxel/carboplatin for advanced non-small cell lung cancer.

Daniel J. Levitt - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Tamibarotene

The challenges of repeat biopsies at acquired resistance to EGFR TKIs.

Meghan Campo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Efficacy of aggressive thoracic therapy (ATT) compared with no ATT for synchronous oligometastatic non-small cell lung cancer (NSCLC): Results of a meta-analysis.

Xiaoxia Zhu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Genomic profiling of lung adenocarcinoma patients reveals potential therapeutic targets when standard molecular testing is negative.

Seungtaek Lim - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Neutrophilia and lymphopenia as prognostic factors in non-small cell lung cancer.

Jaeheon Jeong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Association of biomarkers of insulin resistance and inflammation with PET CT SUV values in stage IV non-small cell lung cancer (NSCLC).

Benjamin Avi Derman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Use of cancer immunotherapies in advanced NSCLC: Persistant challenges among oncologists.

Tara Herrmann - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Assessment of clinical outcomes and prognostic factors in patients (pts) with non-small cell lung carcinoma (NSCLC) and brain metastases (BM): Results from a single institution.

Mariachiara Dipasquale - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Phase II study of erlotinib in advanced non-small cell lung cancer patients with leptomeningeal metastasis.

Kaname Nosaki - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Erlotinib hydrochloride

Molecular mechanism of transformation from adenocarcinoma to small-cell lung cancer after EGFR-TKI.

Jie-Fei Han - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Molecular profile of lung adenocarcinoma in Brazilian never-smokers.

Pedro Masson Domingues - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

An observational study of the efficacy and safety of nivolumab in pretreated patients with advanced non small cell lung cancer (NSCLC): A Galician Lung Cancer Group Clinical Practice.

Carmen Areses Manrique - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Nivolumab

Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort.

Carolyn Jean Presley - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

C-reactive protein (CRP) as a predictive marker for immunotherapy in lung cancer.

Odd Terje Brustugun - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Nivolumab

Phase II study of gefitinib as first-line chemotherapy in patients with advanced non-small cell lung cancer harboring EGFR mutations and poor prognostic characteristics.

Shuji Murakami - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

gefitinib

Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy (RT) in patients (pts) with stage IV NSCLC with disease control after 1st-line chemotherapy or during therapy with an EGFR-TKI: results of an interim analysis.

Martin Sebastian - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

CVac

Clinical characteristics associated with metastatic NSCLC harboring ALK rearrangements in Chinese patients.

Guangming Tian - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts